Krebs Biochemicals & Industries News

Krebs Biochemicals clarifies no material events

Krebs Biochemicals & Industries Limited responds to BSE inquiry about price movement, stating no material information requiring disclosure under SEBI regulations.

Krebs Biochemicals Files Q4FY26 Compliance Certificate

Krebs Biochemicals & Industries Limited submits mandatory SEBI Regulation 74(5) certificate for quarter ended March 31, 2026, confirming compliance with depositories regulations through registrar KFIN Technologies.

Krebs Biochemicals Reports Q3FY26 Loss of ₹312.65 Lacs

Krebs Biochemicals & Industries posted a net loss of ₹312.65 lacs for Q3FY26, with revenue declining 36.55% YoY to ₹727.42 lacs. Manufacturing operations remain closed due to pollution board orders.

Krebs Biochemicals Reports Loss of Rs 1,146.73 Lacs for Half-Year Ended September 2025

Krebs Biochemicals Industries Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported a loss before tax of Rs 1,146.73 lacs for the half-year period, compared to a loss of Rs 2,093.20 lacs in the corresponding period last year. Revenue from operations stood at Rs 1,977.70 lacs for the half-year. The company's cash and cash equivalents decreased to Rs 12.71 lacs as of September 30, 2025, from Rs 14.16 lacs at the beginning of the year. Net cash flow from operating activities was negative at Rs 167.56 lacs. The Board of Directors approved these results in a meeting held on November 4, 2025. The company operates in a single business segment and has no subsidiaries, associates, or joint venture companies.